ASCO 2025: Phase III ARANOTE Post-hoc Analyses Presented on Health-Related Quality of Life and Pain Outcomes in Patients with Metastatic Castration-Sensitive Prostate Cancer Receiving NUBEQA® (darolutamide) plus ADTBusiness Wire • 05/27/25
4 Sizzling Buy-Rated Stocks Trading Under $10 With Massive Upside Potential24/7 Wall Street • 05/11/25
ADT and Yale Introduce First-Ever Z-Wave User Credential Command Class Lock, Expanding Smart Home Security with Fingerprint ControlGlobeNewsWire • 04/30/25
AUA 2025: New Data from Post-Hoc Analyses Shared on Ultra-Low Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Hormone-Sensitive Prostate Cancer Receiving NUBEQA® (darolutamide) plus Androgen Deprivation Therapy (ADT)Business Wire • 04/29/25
ADT Strengthens Executive Leadership Team with Appointments of Fawad Ahmad as Chief Operating and Customer Officer and Omar Khan as Chief Business OfficerGlobeNewsWire • 03/25/25
ADT To Release Fourth Quarter and Full Year 2024 Results On Thursday, Feb. 27, 2025GlobeNewsWire • 02/13/25